Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Identification of a novel… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease.

Artikel i vetenskaplig tidskrift
Författare A H Simonsen
J McGuire
V N Podust
H Davies
Lennart Minthon
Ingmar Skoog
N Andreasen
Anders Wallin
G Waldemar
Kaj Blennow
Publicerad i Neurobiology of aging
Volym 29
Nummer/häfte 7
Sidor 961-8
ISSN 1558-1497
Publiceringsår 2008
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
Sidor 961-8
Språk en
Länkar dx.doi.org/10.1016/j.neurobiolaging...
Ämnesord Aged, Alzheimer Disease, cerebrospinal fluid, diagnosis, Biological Markers, cerebrospinal fluid, Female, Gene Expression Profiling, Humans, Male, Nerve Tissue Proteins, blood, Reproducibility of Results, Sensitivity and Specificity
Ämneskategorier Psykiatri

Sammanfattning

An early and accurate diagnosis of Alzheimer's disease (AD) is required to initiate symptomatic treatment with currently approved drugs and will be of even greater importance if disease modifying compounds in development display a clinical effect. Protein profiles of human cerebrospinal fluid samples from AD patients (n=95) and population-based healthy controls (n=72) were analyzed by SELDI-TOF-MS in order to discover and characterize novel candidate biomarker combinations that differentiate AD patients from normal aging in this explorative study. Thirty candidate biomarkers (ROC AUC>0.7) were discovered that could differentiate patients with AD from healthy controls. Protein sequence determination and positive identification of 15 biomarkers revealed potential associations between the identified markers and AD pathogenesis. A multi-marker combination of five peaks could distinguish AD from healthy control individuals with high sensitivity (97%) and specificity (98%). The panel of five markers was tested on a blinded independent data set of 30 AD samples and 28 controls giving 100% sensitivity and 97% specificity. This novel panel of biomarkers could potentially be used to improve the accuracy of diagnosis of AD.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?